Genentech, Inc.
About Genentech, Inc.
1633 articles with Genentech, Inc.
-
The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Care
3/20/2023
The American Diabetes Association® and Genentech, a member of the Roche Group, announced a new partnership as part of the ADA's Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes community.
-
An independent panel of advisers voted to approve Genentech's Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma.
-
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
3/9/2023
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favor of Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
-
FDA Action Alert: Roche and Acadia
3/6/2023
The FDA's Oncologic Drugs Advisory Committee will meet March 9 to discuss Roche's sBLA for Polivy in first-line DLBCL, while Acadia awaits potential approval of the first therapy for Rett Syndrome. -
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
2/10/2023
Genentech, a member of the Roche Group, announced positive new data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® in macular edema due to branch and central retinal vein occlusion at 24 weeks.
-
Data from a Phase III study show Genentech’s crovalimab is non-inferior to AstraZeneca’s Soliris, the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).
-
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
2/7/2023
Genentech, a member of the Roche Group, announced positive results from the global Phase III COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in people with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.
-
Roche's Tecentriq (atezolizumab) combined with Avastin (bevacizumab) met the primary efficacy endpoint in early-stage hepatocellular carcinoma in the Phase III IMbrave050 study.
-
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
1/19/2023
Genentech, a member of the Roche Group, announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival at the prespecified interim analysis.
-
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
1/9/2023
Kronos Bio, Inc. (Nasdaq: KRON) announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.
-
Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform (Updated)
1/4/2023
Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform. -
Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas
1/4/2023
Belharra Therapeutics today announced a multi-year collaboration with Genentech, a member of the Roche Group.
-
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
12/23/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Lunsumio® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
-
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
12/21/2022
Genentech today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab).
-
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
12/19/2022
Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab.
-
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
-
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
12/12/2022
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.
-
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
12/11/2022
Genentech, a member of the Roche Group, announced interim results from the Phase III HAVEN 7 study.
-
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
12/11/2022
Genentech, a member of the Roche Group, announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy® were presented at the 64th American Society of Hematology Annual Meeting & Exposition, December 10-13.
-
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer.